Deutsche Bank AG Acquires 82,042 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Deutsche Bank AG raised its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 207.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 121,501 shares of the biopharmaceutical company's stock after purchasing an additional 82,042 shares during the quarter. Deutsche Bank AG owned 0.18% of Celldex Therapeutics worth $3,070,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its stake in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 878 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at $81,000. KBC Group NV lifted its position in Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 1,647 shares in the last quarter. AlphaQuest LLC lifted its position in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after buying an additional 2,705 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Celldex Therapeutics during the 4th quarter worth about $121,000.

Celldex Therapeutics Stock Down 0.1%

CLDX traded down $0.02 during trading on Monday, hitting $20.35. The company had a trading volume of 477,438 shares, compared to its average volume of 897,536. The company has a market capitalization of $1.35 billion, a PE ratio of -7.92 and a beta of 1.39. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $47.00. The firm's 50-day moving average price is $18.92 and its 200 day moving average price is $22.31.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. UBS Group dropped their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Canaccord Genuity Group started coverage on Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price target for the company. Finally, The Goldman Sachs Group cut their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $53.90.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.